Recombinant Human Trappin-2/Elafin Protein, CF

• Reactivity: Hu
• Applications: Inhibition Activity
• Format: Carrier-Free

Recombinant Human Trappin-2/Elafin Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit neutrophil elastase cleavage of the fluorogenic peptide substrate, MeOSuc-Ala-Ala-Pro-Val-7-amido-4-methylcoumarin (MeOSuc-AAPV-AMC). The IC₅₀ value is <50 nM, as measured under the described conditions.
• Source: Mouse myeloma cell line, NS0-derived human Trappin-2/Elafin protein
  Ala23-Gln117, with a C-terminal 10-His tag
• Accession #: P19957
• N-terminal Sequence: Ala23
• Protein/Peptide Type: Recombinant Enzymes
• Gene: PI3
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Inhibition Activity
• Theoretical MW: 11 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 13 kDa and 16 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in Tris and NaCl.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Assay Procedure:
  • Activation Buffer: 50 mM MES, 50 mM NaCl, pH 5.5
  • Assay Buffer: 50 mM Tris, 1.0 M NaCl, 0.05% (w/v) Brij-35, pH 7.5
  • Recombinant Human Trappin-2/Elafin (rhTrappin-2) (Catalog # 1747-PI)
  • Recombinant Mouse Neutrophil Elastase/ELA2 (rmELA2) (Catalog # 4517-SE)
  • Recombinant Mouse Active Cathepsin C/DPPI (rmCathepsin C) (Catalog # 2336-CY)
  • Substrate: MeOSuc-Ala-Ala-Pro-Val-AMC (Bachem, Catalog # I-1270), 10 mM stock in DMSO
  • F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
  • Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent
  1. Dilute rmELA2 to 50 µg/mL in Activation Buffer containing 50 μg/mL rmCathepsin C.
  2. Incubate 50 µg/mL rmELA2 at 37 °C for 2 hours to activate.
  3. Prepare a dilution curve of rhTrappin-2 (MW: 16,000 Da) in Assay Buffer. Make serial dilutions of: 3200, 1600, 800, 600, 400, 200, 100, and 10 nM.
  4. Dilute activated rmELA2 to 10 µg/mL with Assay Buffer.
  5. Combine each dilution of rhTrappin-2 with rmELA2 in equal volumes. Include two rmELA2 controls containing equal volumes of rmELA2 and Assay Buffer without any rhTrappin-2.
  6. Incubate reactions at room temperature for 10 minutes.
  7. Dilute each reaction five-fold with Assay Buffer.
  8. Dilute Substrate to 200 µM in Assay Buffer.
  9. Load 50 µL of the diluted incubated curve into a black well plate, and start the reaction by adding 50 µL of 200 µM Substrate.
  10. Read at excitation and emission wavelengths of 380 nm and 460 nm (top read), respectively, in kinetic mode for 5 minutes.
  11. Derive the 50% inhibiting concentration (IC₅₀) for rhTrappin-2 by plotting RFU/min (or specific activity) vs. concentration with 4-PL fitting.
  12. The specific activity of rmELA2 at each point may be determined using the following equation (if desired):

  Specific Activity (pmol/min/µg) = (Adjusted Vmax* (RFU/min) x Conversion Factor** (pmol/RFU)) / (amount of enzyme (µg))

  *Adjusted for Substrate Blank
  **Derived using calibration standard 7-Amino, 4-Methyl Coumarin (AMC) (Sigma, Catalog # A-9891).

  Per Well:
  • rhTrappin-2: 160, 80, 40, 30, 20, 10, 5 and 0.5 nM
  • rmELA2: 0.05 µg
  • Substrate: 100 µM

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Trappin-2/Elafin Protein, CF

• cementoin
• Elafin
• Elastase-specific inhibitor
• ESI
• ESIWAP four-disulfide core domain protein 14
• Peptidase inhibitor 3
• peptidase inhibitor 3, skin-derived
• PI3
• PI-3
• pre-elafin
• protease inhibitor 3, skin-derived (SKALP)
• Protease inhibitor WAP3
• SKALP
• SKALPELAFIN
• Skin-derived antileukoproteinase
• Trappin2
• Trappin-2
• WAP four-disulfide core domain 14
• WAP3MGC13613
• WFDC14elafin

Background

Trappin-2 is the human member of the trappin gene family that contains SLPI (1). Trappin-2 consists of an N-terminal transglutaminase substrate domain (residues 23‑60) and a C-terminal four-disulfide core or whey acidic protein (WAP) domain (residues 72‑117). Elafin or ESI (elastase-specific inhibitor) and SKALP (skin‑derived anti‑leucoproteinase) are alternative names for Trappin-2 and reflect its protease targets. However, elafin and SKALP sometimes correspond only to the processed form that contains the C-terminal WAP domain of the molecule, which can be isolated naturally. The recombinant human Trappin-2 corresponds to the full‑length form (residues 23‑117), which migrates as two protein bands under SDS-PAGE due to an unidentified mechanism. In addition to its ability to inhibit human neutrophil elastase, it can also be used as a substrate for transglutaminases.

1. Schalkwijk, J. et al. (1999) Biochem. J. 340:569.

Publications for Trappin-2/Elafin/Skalp (1747-PI)(6)

Publications using 1747-PI

• J Cassuto, A Folestad, J Göthlin, H Malchau, J Kärrholm Concerted actions by MMPs, ADAMTS and serine proteases during remodeling of the cartilage callus into bone during osseointegration of hip implants Bone Rep, 2020-09-11;13(0):100715. 2020-09-11 [PMID: 32995386] (ELISA Detection, Human)
• Labidi-Galy S, Clauss A, Ng V, Duraisamy S, Elias K, Piao H, Bilal E, Davidowitz R, Lu Y, Badalian-Very G, Gyorffy B, Kang U, Ficarro S, Ganesan S, Mills G, Marto J, Drapkin R Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene, 2014-01-27;34(3):373-83. 2014-01-27 [PMID: 24469047] (Bioassay, Human)
• Drannik AG, Nag K, Yao XD, Henrick BM, Sallenave JM, Rosenthal KL Trappin-2/elafin modulate innate immune responses of human endometrial epithelial cells to PolyI:C. PLoS ONE, 2012-04-24;7(4):e35866. 2012-04-24 [PMID: 22545145] (Enzyme Assay, Human)
• Drannik AG, Nag K, Yao XD, Henrick BM, Jain S, Ball TB, Plummer FA, Wachihi C, Kimani J, Rosenthal KL Anti-HIV-1 activity of elafin is more potent than its precursor&#039;s, trappin-2, in genital epithelial cells. J. Virol., 2012-02-15;86(8):4599-610. 2012-02-15 [PMID: 22345469] (Bioassay, Human)
• Wilkinson TS, Dhaliwal K, Hamilton TW, Lipka AF, Farrell L, Davidson DJ, Duffin R, Morris AC, Haslett C, Govan JR, Gregory CD, Sallenave JM, Simpson AJ Trappin-2 promotes early clearance of Pseudomonas aeruginosa through CD14-dependent macrophage activation and neutrophil recruitment. Am. J. Pathol., 2009-03-05;174(4):1338-46. 2009-03-05 [PMID: 19264904] (In Vivo, Mouse)
• Cortesio CL, Jiang W Mannan-binding lectin-associated serine protease 3 cleaves synthetic peptides and insulin-like growth factor-binding protein 5. Arch. Biochem. Biophys., 2006-03-03;449(1):164-70. 2006-03-03 [PMID: 16554018] (Enzyme Assay)

Bioinformatics

• Gene Symbol: PI3
• Uniprot:
  • P19957()